Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXY - Maxygen, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (36)	9/15/2000 9:05:17 AM
From: nigel bates	Read Replies (1) \| Respond to of 262

Sept. 15 /PRNewswire/ -- Maxygen, Inc. (Nasdaq: MAXY - news) today announced that it has established a research and screening collaboration with The Scripps Research Institute to identify potential vaccine candidates for the treatment and prevention of HIV. Maxygen will use its proprietary MolecularBreeding(TM) directed molecular evolution technologies to create novel antigens capable of generating immune responses against the HIV virus. Dennis Burton, Ph.D., and Paul Parren, Ph.D., of The Scripps Institute will analyze the novel antigens for their ability to immunize against the HIV virus. ``We are pleased to have this relationship with two outstanding HIV specialists at The Scripps Institute,'' said Robert Whalen, Senior Research Fellow at Maxygen. ``This work will allow us to demonstrate the potential of our proprietary directed evolution technologies and their application in preventing this devastating disease.'' The Scripps Research Institute is one of the country's largest, private, non-profit research organizations. The Institute stands at the forefront of basic biomedical science, a vital segment of medical research that seeks to understand the fundamental processes of life. In just three decades the Institute has established a lengthy track record of major contributions to the betterment of health and the human condition.